The frequency of missed breast cancers in women participating in a high-risk MRI screening program
AbstractPurposeTo evaluate the frequency of missed cancers on breast MRI in women participating in a high-risk screening program.MethodsPatient files from women who participated in an increased risk mammography and MRI screening program (2003 –2014) were coupled to the Dutch National Cancer Registry. For each cancer detected, we determined whether an MRI scan was available (0–24 months before cancer detection), which was reported to be negative. These negative MRI scans were in consensus re-evaluated by two dedicated breast radiolog ists, with knowledge of the cancer location. Cancers were scored as invisible, minimal sign, or visible. Additionally, BI-RADS scores, background parenchymal enhancement, and image quality (IQ; perfect, sufficient, bad) were determined. Results were stratified by detection mode (mammography, MRI, in terval cancers, or cancers in prophylactic mastectomies) and patient characteristics (presence ofBRCA mutation, age, menopausal state).ResultsNegative prior MRI scans were available for 131 breast cancers. Overall 31% of cancers were visible at the initially negative MRI scan and 34% of cancers showed a minimal sign. The presence of aBRCA mutation strongly reduced the likelihood of visible findings in the last negative MRI (19 vs. 46%,P
Studies have demonstrated increased breast cancer risk associated with postmenopausal hormone therapy, but does risk vary depending on dose, formulation, and route of delivery of estrogen-alone HT?Menopause
(The North American Menopause Society (NAMS)) Vitamin D is already well known for its benefits in building healthy bones. A new study supports the idea that it also may reduce cancer risk as well as breast cancer mortality, especially in women with a lower body mass index. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).
ConclusionsOur findings showed that an unhealthy dietary pattern might be associated with higher risk of breast among Iranian women.
Objective: Approximately 50% to 70% of breast cancer survivors are affected by one or more symptoms of vulvovaginal atrophy (VVA). For those who cannot take hormone therapy, autologous platelet-rich plasma combined with hyaluronic acid (A-PRP-HA) may provide a new alternative therapy for the treatment of VVA in postmenopausal women with history of breast cancer. Methods: We enrolled 20 postmenopausal breast cancers survivors with VVA and a score of
No abstract available
You may have to cope with an altered body image and a treatment-induced menopause, but don ’t let cancer take away your physical connection, says Dr Liz O'Riordan, who was diagnosed in 2015.
ConclusionsPhysical activity is not a determinant of MD.
Condition: Breast Neoplasms Interventions: Drug: Xentuzumab; Drug: Placebo; Drug: Everolimus; Drug: Exemestane Sponsor: Boehringer Ingelheim Not yet recruiting
Conclusions: This study identified the predictors of new-onset psychological distress available in routinely collected administrative health databases, and showed how predictors change between hospital-based treatment and transitional survivorship periods. The results highlight the importance of developing predictive models tailored to the period of cancer care. PMID: 30181418 [PubMed - in process]